Ann: Response to ASX Price Query, page-10

I think the most positive thing here is that the company has a good plan and is achieving milestones. Having a number of products at various stages of development is also a huge plus as it diversifies investor risk. For me, this is exactly what you want to see in a biotech. Considering some of the other speculative biotechs on the ASX at this point in time and the market caps they have, it would appear that RGS could be quite undervalued so I'm glad to be involved at such an early stage. I think this could be very rewarding in the short and long term; the only thing we need to be wary of is the cash position and when they need to raise capital. Seeing a partnering deal (i.e. Japan) would be a huge step in the right direction and if the company moves to a position where it is self funding over the longer term I would imagine this will appear to many more investors.